About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. | As pharmas ...

They aren't just "pandemic stocks." ...

More than 5,000 shelved drug candidates were discontinued for business reasons, not safety ones. A new push aims to match them with the highest need.

Pfizer Inc (NYSE:PFE) develops medicines and vaccines across multiple therapeutic areas, contributing to the S&P 500 ...

Novo Nordisk and Pfizer's multibillion-dollar fight over who gets to buy an anti-obesity biotech has morphed into a narrative argument over which acquisition would be most America First — a framing ...

CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer and ...

These companies have impressive track records of navigating the biggest challenges in their industry.

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.